Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$1.20 USD
-0.07 (-5.51%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $1.21 +0.01 (0.83%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Brokerage Reports
Nektar Therapeutics [NKTR]
Reports for Purchase
Showing records 1 - 20 ( 397 total )
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Nektar Therapeutics
Industry: Medical - Drugs
Company: Nektar Therapeutics
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department